Rosuvastatin - A highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: Review of clinical trial data at 10-40 mg doses in dyslipidemic patients

Cardiology

Volumn 99, Issue 3, 2003, Pages 126-139

  Schuster, Herbert ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b INFOGEN GmbH   (Germany)

Author keywords

Diabetes; Dyslipidemia; Hypercholesterolemia; Hypercholesterolemia, familial; Hyperlipidemia; Rosuvastatin; Statin

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ALUMINUM; ANTACID AGENT; ANTIVITAMIN K; ATORVASTATIN; CYCLOSPORIN; ENZYME INHIBITOR; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM HYDROXIDE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; WARFARIN;

CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE SEVERITY; DOSE CALCULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EUROPE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; MEDICAL EDUCATION; MONOTHERAPY; PRIORITY JOURNAL; REVIEW;

ADULT; AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0037970200     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070669     Document Type: Review

References (79)

1. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998;279:1616-1622.
2. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
3. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002;360:7-22.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
5. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497 (full report available at www.nhlbi.nhi.gov).
8. EUROASPIRE I and II Group: Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357:995-1001.
9. Vale MJ, Jelinek MV, Best JD: How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996-1998 versus 1999-2000. Med J Aust 2002;176:211-215.
10. Pearson TA, Laurora I, Chu H, Kafonek S: The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-467.
11. Istvan ES, Deisenhofer J: Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292:1160-1164.
12. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M: Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87(suppl):28B-32B.
13. Holdgate GA, Ward WHJ, Davidson RG, Thornton M, March R, McTaggart F: Kinetics of inhibition of HMG-CoA reductase by a new statin, rosuvastatin (abstract 174). Atherosclerosis 2001(suppl 2/2):90.
14. Buckett L, Ballard P, Davidson R, Dunkley C, Martin L, Stafford J, McTaggart F: Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells. Atherosclerosis 2000;151:41.
15. Nezasa K, Higaki K, Hasegawa H, Inazawa K, Takeuchi M, Yukawa T, McTaggart F, Nakano M: Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat. Atherosclerosis 2000;151:39.
16. Chapman MJ, McTaggart F: Optimizing the pharmacology of statins: Characteristics of rosuvastatin. Atherosclerosis Suppl 2002;2:33-37.
17. Martin PD, Dane AL, Schneck DW, Warwick MJ: Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects. J Clin Pharmacol 2000;40:1056.
18. McCormick AD, McKillop D, Butters CJ, Miles GS, Baba T, Touchi A, Yamaguchi Y: ZD4522 - An HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems. J Clin Pharmacol 2000;40:1055.
19. Martin PD, Cooper KJ, Dane AL, Warwick MJ, Schneck DW, Nwose OM: Ketoconazole has no clinically relevant effect on the pharmacokinetics of rosuvastatin (abstract 286). Pharmacol Toxicol 2001;89(suppl 1):75.
20. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Nwose OM: Erythromycin has no clinically relevant effect on the pharmacokinetics of rosuvastatin (abstract 287). Pharmacol Toxicol 2001;89(suppl 1):75.
21. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini M: Fluconazole has no clinically relevant effect on the pharmacokinetics of rosuvastatin (abstract 288). Pharmacol Toxicol 2001;89(suppl 1):75.
22. Martin PD, Mitchell PD, Schneck DW: Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy subjects. Br J Clin Pharmacol 2002;54:472-477.
23. Martin PD, Dane AL, Nwose D, Schneck DW, Warwick MJ: No effects of age or gender on the pharmacokinetics of rosuvastatin - A new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002;42:1116-1121.
24. CRESTOR®(prescribing information): Summary of the Product Characteristics (07/03/03). Macclesfield, AstraZeneca, 2003.
25. Stalker TJ, Lefer AM, Scalia R: A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: The role of mevalonic acid. Br J Pharmacol 2001;133:406-412.
26. Havekes LM, Van Duyvenvoorde W, Maas MCE, Van Der Boom H, Van Den Hoogen CM, Emeis JJ, Princen HMG: Rosuvastatin reduces atherosclerosis independently of its cholesterol-lowering effect in ApoE3*Leiden transgenic mice. Atherosclerosis Suppl 2002;3:187.
27. Laufs U, Gertz K, Dirnagl U, Böhm M, Nickenig G, Endres M: Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002;942:23-30.
28. Cameron NE, Inkster ME, Nangle MR, Smith GJ, McTaggart F, Cotter MA: Effects of rosuvastatin (Crestor™) on neurovascular function in diabetic rats. Diabetes 2001;50(suppl 2):A184.
29. Jones P, Kafonek S, Laurora I, Hunninghake D: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol 1998;81:582-587.
30. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH: Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001;111:185-191.
31. Olsson AG, McTaggart F, Raza A: Rosuvastatin: A highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002;20:303-328.
32. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, for the STELLAR Study Group: Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol, in press.
33. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG: Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 2003;91:33-41.
34. Data on file: Macclesfield, AstraZeneca.
35. Schuster H: Effects of switching to rosuvastatin from atorvastatin or other statins on achievement of international low-density lipoprotein cholesterol goals: MERCURY I trial. MERCURY I study group (abstract 1010-149). J Am Coll Cardiol 2003(suppl):227A-228A.
36. Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, Hutchinson H: Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002;89:268-275.
37. Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O, Southworth H, Pears J, Wilpshaar JW: Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002;144:1044-1051.
38. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H: Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: A randomized, double-blind study. J Cardiovasc Risk 2001;8:383-390.
39. Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, Miller E: Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. Am Heart J 2002;144:1036-1043.
40. Blasetto J, Stein E, Brown WV, Chitra R, Raza A: Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003;91(suppl 5A):3C-10C.
41. Second Joint Task Force: Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998;19:1434-1503.
42. EUROASPIRE II Study Group: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-572.
43. Sueta CA, Chowdhury M, Boccuzzi SJ, Smith SC Jr, Alexander CM, Londhe A, Lulla A, Simpson RJ Jr: Analysis of the degree of under-treatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999;83:1303-1307.
44. Fonarow GC, Ballantyne CM: In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: The time is now. Circulation 2001;103:2768-2770.
45. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
46. Shepherd J, Hunninghake DB, Barter P, McKenney J, Hutchinson H: Guidelines for lowering lipids to reduce coronary heart disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003;91(suppl 5A):11C-19C.
47. Assmann G, Schulte H, Funke H, Von Eckardstein A: The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998;19(suppl M):M8-M14.
48. Cullen P: Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000;86:943-949.
49. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-219.
50. Hodis HN, Mack WJ: Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol 1995;6:209-214.
51. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97:1029-1036.
52. Hunninghake DB, Chitra RR, Simonson SG, Schneck DW: Rosuvastatin markedly improved the atherogenic profile in hypertriglyceridaemic patients. Eur Heart J 2001;22(suppl):270.
53. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL: Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161:1413-1419.
54. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C: Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: Effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. ACCESS Study Group. Am J Cardiol 2001;88:265-269.
55. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 2001;358:2026-2033.
56. Frost PH, Havel RJ: Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 1998;81/4a:26b-31b.
57. Rader DJ, Davidson MH, Caplan RJ, Pears JS: Lipid and apolipoprotein ratios: Association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am J Cardiol 2003;91(suppl):20C-24C.
58. Stein E, Strutt KL, Miller E, Southworth H: ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2001;37(suppl A):292A.
59. Stein E, Strutt KL, Miller E, Southworth H: Rosuvastatin (20, 40 and 80 mg) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 2001;2(suppl):90.
60. Marais D, Raal F, Stein E, Rader D, Smith K, Blasetto J, Wilpshaar W: Effect of rosuvastatin on LDL-cholesterol, mevalonic acid and other lipid measurements in patients with homozygous familial hypercholesterolaemia. Atherosclerosis Suppl 2002;3:159.
61. Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, Cressman MD: Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 2003;91:1304-1310.
62. Durrington P, Hamann A, Tuomilehto J, Smith K, Kallend D: Rosuvastatin alone and in combination with fenofibrate in hyperlipidaemic patients with type 2 diabetes. Diabetologia 2001;44(suppl 1):A165.
63. Durrington PN, Tuomilehto J, Hamann A, Southworth H, Pears J, Kallend D: Effects of rosuvastatin alone and in combination with fenofibrate on lipid subfractions in patients with type 2 diabetes: Results at 24 weeks. Circulation 2001;104(suppl II):II-177.
64. Lipitor (prescribing information); in Physician's Desk Reference. Montvale, Medical Economics, 2003, pp 2610-2613.
65. Zocor (prescribing information); in Physician's Desk Reference. Montvale, Medical Economics, 2003, pp 2126-2131.
66. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV: The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002;58:527-531.
67. Martin PD, Cooper KJ, Dane AL, Warwick MJ, Nwose OM, Cantarini M: Itraconazole produces modest increases in rosuvastatin plasma concentrations (abstract 297). Pharmacol Toxicol 2001;89(suppl 1):77-78.
68. Martin PD, Kemp J, Dane AL, Warwick MJ, Schneck DW: No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 2002;42:1352-1357.
69. Martin P, Dane A, Schneck D, Warwick M: An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003;25:459-471.
70. Backman JT, Kyrklund C, Kivisto K, Wang JS, Neuvonen PJ: Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000;68:122-129.
71. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ: Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001;69:340-345.
72. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ: Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002;72:685-691.
73. Pravachol (prescribing information); in Physician's Desk Reference. Montvale, Medical Economics, 2003, pp 1101-1106.
74. Mevacor (prescribing information); in Physician's Desk Reference. Montvale, Medial Economics, 2003, pp 2036-2041.
75. Lescol (prescribing information); in Physician's Desk Reference. Montvale, Medical Economics, 2003, pp 2283-2287.
76. Baycol (prescribing information); in Physician's Desk Reference. Montvale, Medical Economics, 2001, pp 843-846.
77. Brown CDA, Windass A, Bleasby K, Lauffart B: Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C (abstract 166). Atherosclerosis 2001;suppl 2/2:88.
78. Asberg A: Interactions between cyclosporin and lipid-lowering drugs: Implications for organ transplant recipients. Drugs 2003;63:367-378.
79. Fedder DO, Koro CE, L'Italien GJ: New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: Projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002;105:152-156.